St Mary's Hospital, Portsmouth.
1471-0528/asset/BJO_left.gif?v=1&s=0fb87361cdb6be25fdf05019eed6d47f5143f610)
1471-0528/asset/olbannerright.gif?v=1&s=3892ef16ff18d6834c302faf85268a49f5fc588f)
Endocrine effects of danazol in the treatment of endometriosis
Article first published online: 23 AUG 2005
DOI: 10.1111/j.1471-0528.1984.tb05901.x
Issue
1471-0528/asset/cover.gif?v=1&s=b4e1d96c46e18c61210d584b63c13ee375cf562b "BJOG: An International Journal of Obstetrics & Gynaecology")
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 91, Issue 2, pages 160–166, February 1984
Additional Information
How to Cite
BEVAN, J. R., DOWSETT, M. and JEFFCOATE, S. L. (1984), Endocrine effects of danazol in the treatment of endometriosis. BJOG: An International Journal of Obstetrics & Gynaecology, 91: 160–166. doi: 10.1111/j.1471-0528.1984.tb05901.x
Publication History
- Issue published online: 23 AUG 2005
- Article first published online: 23 AUG 2005
- Received 12 April 1983; Accepted 10 August 1983
- Abstract
- References
- Cited By
summary
The effects of danazol therapy on circulating gonadotrophins, oestradiol and sex hormone-binding globulin (SHBG) binding capacity have been studied in eight patients with endometriosis. There was a significant rise in luteinizing hormone (LH) in the first week of treatment with a fall in oestradiol levels. There was a marked fall in SHBG in the first week which continued up to 4 weeks. It is concluded that danazol is not ‘antigonadotrophic’ as frequently claimed and that its therapeutic actions, side effects and the endocrine changes could be explained by an effect on SHBG production. The rationale of its use in other conditions requires reconsideration.